

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

FoxO1 (C29H4) Rabbit mAb (Alexa Fluor® 647 Conjugate)

RRID:AB_2799829

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 72874, RRID:AB_2799829

Antibody Information

URL: http://antibodyregistry.org/AB_2799829

Proper Citation: Cell Signaling Technology Cat# 72874, RRID:AB_2799829

Target Antigen: FOXO1A

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: F

Antibody Name: FoxO1 (C29H4) Rabbit mAb (Alexa Fluor® 647 Conjugate)

Description: This monoclonal targets FOXO1A

Target Organism: h, m, r, mk

Clone ID: Clone C29H4

Antibody ID: AB_2799829

Vendor: Cell Signaling Technology

Catalog Number: 72874

Record Creation Time: 20250819T234141+0000

Record Last Update: 20250820T060823+0000

Ratings and Alerts

No rating or validation information has been found for FoxO1 (C29H4) Rabbit mAb (Alexa Fluor® 647 Conjugate).

No alerts have been found for FoxO1 (C29H4) Rabbit mAb (Alexa Fluor® 647 Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Farré Díaz C, et al. (2026) FOXO1 re-expression with a dual-recombinase allele rescues class switching in germinal center B cells. The Journal of experimental medicine, 223(3).

Tallan A, et al. (2026) Comparative modes of chromatin engagement by PAX::FOXO1 fusions in rhabdomyosarcoma. bioRxiv : the preprint server for biology.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Cox EM, et al. (2023) AKT activity orchestrates marginal zone B cell development in mice and humans. Cell reports, 42(4), 112378.

Shemesh A, et al. (2022) Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcγRI? expression. The Journal of experimental medicine, 219(11).